ReviewViruses2023
HLA Variation and SARS-CoV-2 Specific Antibody Response.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 25 citations in OpenAlex.
- Protein M of NADC30-like PRRSV induces MARCH6-mediated K33-linked polyubiquitination of SLA-DRA.The Journal of biological chemistry · 2026Article
- In Silico-Identified Peptides of FiveBiology · 2026Article
- Integrating Host Genetics and Clinical Setting in Machine Learning Models: Predicting COVID-19 Prognosis for Healthcare Decision-Making (The FeMiNa Study).Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Genetically Validated Immune Susceptibility Markers for Crohn's Disease: A Multi-Omics Mendelian Randomization Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Longitudinal analysis of hybrid immunity in a Vietnamese COVID-19 cohort demonstrates vaccination-associated broadening of cross-variant neutralization across diverse HLA backgrounds.Frontiers in immunology · 2026Article
- A multi-epitope pan-betacoronavirus vaccine construct predicted to induce broad-spectrum and durable immune responses: an immunoinformatics approach.Frontiers in bioinformatics · 2026Article
- Associations between genetic variations of HLA and IGHV, vaccination schedule, and COVID-19 vaccine immunogenicity.NPJ vaccines · 2025Article
- HLA and pathogens in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other post-infection conditions.Scientific reports · 2025Article
- Situation Analysis of Immune Response Status One Year After the Nationwide COVID-19 Vaccination in Cameroon: Role of Obesity and SARS-CoV-2 Infection.Health science reports · 2025Article
- Review
- Associations between HLA-II variation and antibody specificity are predicted by antigen properties.Genome medicine · 2025Article
- Analyzing the impact of human leukocyte antigen mismatch on the incidence of prostate cancer and the advantage of T cell therapy in patients after kidney transplantation based on the United Network for Organ Sharing database.Frontiers in oncology · 2025Article
- Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2.Pharmaceuticals (Basel, Switzerland) · 2024Article
- HLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- Review
- Article
- The Human Genetic Differences in the Outcomes of mRNA Vaccination against COVID-19: A Prospective Cohort Study.Vaccines · 2024Article
- Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.Communications medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Differences in SARS-CoV-2-specific immune responses have been observed between individuals following natural infection or vaccination. In addition to already known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination status, hybrid immunity, and duration of infection, inter-individual variations in SARS-CoV-2 immune responses may, in part, be explained by structural differences brought about by genetic variation in the human leukocyte antigen (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T effector cells. While dendritic cells present peptides with HLA class I molecules to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present peptides with HLA class II molecules to T follicular helper cells to induce B cell differentiation followed by memory B cell and plasma cell maturation. Plasma cells then produce SARS-CoV-2-specific antibodies. Here, we review published data linking HLA genetic variation or polymorphisms with differences in SARS-CoV-2-specific antibody responses. While there is evidence that heterogeneity in antibody response might be related to HLA variation, there are conflicting findings due in part to differences in study designs. We provide insight into why more research is needed in this area. Elucidating the genetic basis of variability in the SARS-CoV-2 immune response will help to optimize diagnostic tools and lead to the development of new vaccines and therapeutics against SARS-CoV-2 and other infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.